Maria Ostrovsky became General Counsel of Candel Therapeutics on November 3, 2026, per the SEC Form 3 filed November 5, 2026. A Form 3 is the first ownership report a new officer files, due within 10 days of taking the role.
Who to call at Candel Therapeutics, and when
A new leader at Candel Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day Candel Therapeutics raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Candel Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Candel Therapeutics. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Candel Therapeutics
Location
Needham, Massachusetts, United States
About
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer. The company is known for its first-in-class oncolytic viral immunotherapy candidate, CAN-3110, which targets Nestin-positive tumors. They aim to extend cancer treatment options beyond traditional methods and focus on innovative therapeutic approaches. Candel aims to address unmet medical needs in oncology with its experimental medicines.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Candel Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
NeedhamBiotechnologyHealth CareTherapeuticsBiopharma